Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials

Purpose The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic treatment for HR+/HER2− patients who do not achieve a pathological complete response. Methods Stromal (Str) TIL were centrally evaluated on samp...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2017-06, Vol.163 (2), p.295-302
Main Authors: Dieci, M. V., Frassoldati, A., Generali, D., Bisagni, G., Piacentini, F., Cavanna, L., Cagossi, K., Puglisi, F., Michelotti, A., Berardi, R., Banna, G., Goubar, A., Ficarra, G., Griguolo, G., Conte, Pierfranco, Guarneri, V.
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
Breast cancer
Cancer research
Cancer therapies
Care and treatment
Clinical Trial
Clinical trials
Lymphocytes
Medicine
Medicine & Public Health
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic treatment for HR+/HER2− patients who do not achieve a pathological complete response. Methods Stromal (Str) TIL were centrally evaluated on samples from diagnostic core-biopsies of HR+/HER2− patients included in two prospective randomized trials: the LETLOB trial (neoadjuvant endocrine-based treatment) and the GIOB trial (neoadjuvant chemotherapy-based treatment). Pre- and post-treatment Ki67 was centrally assessed. Results StrTIL were evaluable in 111 cases ( n  = 73 from the LETLOB trial and n  = 38 from the GIOB trial). Median StrTIL was 2%. Patients with high StrTIL (StrTIL ≥10%, n  = 28) had more frequently breast cancer of ductal histology ( p  = 0.02), high grade ( p  = 0.049), and high Ki67 ( p  = 0.02). After neoadjuvant endocrine treatment (LETLOB cohort), a significant Ki67 suppression ( p  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-017-4191-y